Actually, the first clinical trials with CB2R selective agonists, such as NTRX-07 in healthy volunteers (Phase 1, NCT04375436), JBT-101 for cystic fibrosis and systemic lupus erythematosus (Phase 2, NCT03451045, NCT03093402) and CB2R antagonists, such as TT-816 in combination with a Programmed cell death protein 1 (PD-1) inhibitor for different cancer entities (Phase 1/2, NCT05525455) are being conducted (Kosar et al. 2024). This evidence concerns the gene PDCD1 and systemic lupus erythematosus.